iguratimod has been researched along with Duncan Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto-Hirakawa, Y; Fukuda, W; Iwai, T; Kobayashi, T; Kuriyama, K; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagata, H; Nishikawa, R; Ohshiro, M; Shimura, Y; Tsukamoto, T; Uchiyama, H; Yamamoto-Sugitani, M | 1 |
| Hagihara, M; Hua, J; Ide, S; Inoue, M; Mese, T; Ohara, S | 1 |
2 other study(ies) available for iguratimod and Duncan Disease
| Article | Year |
|---|---|
Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Female; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Methotrexate; Recurrence; Sulfonamides | 2021 |
Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis: A Very Rare Case.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Methotrexate; Neoplasm Recurrence, Local; Rare Diseases; Rituximab; Sulfonamides; Treatment Outcome | 2018 |